There is no single best treatment for MS—the right one depends on your type of MS, how active it is, and how your body responds

Multiple sclerosis treatment falls into two main categories: disease-modifying therapies (DMTs), which slow the progression of the disease, and symptom management, which addresses pain, fatigue, mobility problems, and other effects you experience day to day. Most people with MS take a DMT as their foundation and add other treatments as needed for specific symptoms. What works best for one person may not work for another, which is why your neurologist will monitor your response and adjust your plan over time.

The choice of treatment also depends on whether you have relapsing-remitting MS (where you have periods of new or worsening symptoms followed by periods of stability), progressive MS (where symptoms gradually worsen over time), or a form in between. Your neurologist will discuss the options that match your diagnosis and disease activity, along with the side effects and monitoring each one requires.

Key Takeaways

  • Disease-modifying therapies are the foundation of MS treatment and work by reducing inflammation or suppressing immune activity; starting one early is associated with better long-term outcomes.
  • Different DMTs have different routes (injections, infusions, oral pills), different monitoring requirements, and different side effect profiles—your neurologist will help match one to your situation.
  • Symptom management treatments address fatigue, pain, spasticity, and mobility separately from the disease-modifying drug and are often needed alongside it.
  • Treatment plans change over time; if a DMT stops working or causes side effects, your neurologist can switch you to a different one.
  • The goal of modern MS treatment is to reach "no evidence of disease activity" (NEDA), meaning no new relapses, no new brain lesions, and no worsening disability.

How disease-modifying therapies work and why they matter

Disease-modifying therapies reduce the number and severity of relapses and slow the accumulation of disability over time. They work by either dampening the immune system's attack on the nervous system or by reducing inflammation in the brain and spinal cord. Starting a DMT early—ideally within weeks of diagnosis—is associated with better outcomes over the long term, even if your MS seems mild at first.

DMTs do not cure MS or reverse existing damage. They reduce the rate at which new damage occurs. This is why neurologists emphasize starting treatment promptly: the goal is to prevent new relapses and new lesions before they happen, not to wait and see how active your disease is.

Your neurologist will choose a DMT based on your type of MS, how active it is (measured by relapse rate and new lesions on MRI), your age, whether you plan to become pregnant, other health conditions you have, and whether you have had any prior MS treatments. Some DMTs are considered first-line options for newly diagnosed people; others are reserved for people whose disease is more active or who have not responded to a first-line drug.

The main categories of disease-modifying drugs

Interferon beta drugs (Avonex, Betaseron, Rebif) are injected weekly or three times a week. They reduce relapse rates by about 30 percent. They have been used for decades and are well understood, but they require frequent injections and can cause flu-like side effects.

Glatiramer acetate (Copaxone, Glatopa) is injected daily or three times weekly. It works by mimicking a protein in the nervous system and redirecting immune cells away from myelin. Relapse reduction is similar to interferon beta, around 30 percent.

Monoclonal antibodies (natalizumab, alemtuzumab, ocrelizumab, ublituximab) are given by infusion, usually monthly or quarterly. They target specific immune cells or proteins involved in the attack on the nervous system. They tend to reduce relapses more effectively than interferon or glatiramer—often by 50 to 70 percent—but require closer monitoring because they carry higher risks of infection or other immune complications.

Oral medications (fingolimod, dimethyl fumarate, teriflunomide, siponimod, ozanimod) are pills taken daily or twice daily. They work through different mechanisms—some reduce lymphocyte counts, others reduce inflammation. They are convenient because they do not require injections or infusions, but they also require regular blood work and monitoring.

S1P receptor modulators (fingolimod, siponimod, ozanimod) prevent immune cells from leaving lymph nodes and entering the nervous system. They are oral and relatively effective, but they require baseline heart and eye exams because they can affect heart rate and vision.

What happens after you start a DMT

Your neurologist will schedule follow-up appointments and MRI scans to see how you are responding. Most people have an MRI 3 to 6 months after starting a new DMT to check for new lesions. If you are relapse-free and have no new lesions on MRI, the drug is working as intended. If you have a relapse or new lesions appear, your neurologist may increase the dose, switch to a different DMT, or add another medication.

Different DMTs require different monitoring schedules. Monoclonal antibodies typically require blood work every few months and sometimes additional screening (such as JC virus testing for natalizumab). Oral medications require regular blood counts and liver function tests. Interferon and glatiramer require less frequent monitoring but still need periodic check-ins.

Side effects vary widely. Some people tolerate their first DMT well for years; others experience side effects that prompt a switch. Common side effects include injection-site reactions, flu-like symptoms, nausea, headache, and fatigue. More serious but less common side effects include infections, liver damage, or heart rhythm changes—which is why monitoring matters.

Treating specific MS symptoms

While a DMT addresses the underlying disease, you may also need separate treatments for the symptoms MS causes. Fatigue, one of the most common and disabling symptoms, is sometimes treated with amantadine, methylphenidate, or modafinil. Physical therapy and pacing strategies also help.

Spasticity (muscle stiffness and involuntary contractions) may be managed with baclofen, tizanidine, or cannabis-based products in states where they are available. Physical therapy and stretching are also important. Pain from MS can be neuropathic (nerve pain) or musculoskeletal; neuropathic pain often responds to gabapentin, pregabalin, or duloxetine.

Mobility and balance problems are addressed through physical therapy, occupational therapy, and sometimes assistive devices. Bladder and bowel symptoms may require medications, intermittent catheterization, or dietary changes. Cognitive symptoms (memory, concentration) are harder to treat pharmacologically but may improve with cognitive rehabilitation and lifestyle changes.

The point is that symptom management is separate from disease modification. You may be on a DMT that is controlling relapses while also taking medications or doing therapies that address the day-to-day effects of the disease.

Progressive MS and treatment differences

Progressive forms of MS—primary progressive, secondary progressive, and progressive-relapsing—are treated differently than relapsing-remitting MS. For many years, few DMTs worked well for progressive MS, but newer drugs have shown benefit. Ocrelizumab has been shown to slow progression in primary progressive MS. Siponimod slows progression in secondary progressive MS.

Progressive MS is harder to treat because it involves different immune mechanisms than relapsing-remitting disease. Relapses are less frequent or absent, so the goal shifts from preventing relapses to slowing the steady accumulation of disability. Treatment decisions for progressive MS are more individualized, and your neurologist may recommend a DMT even if you have not had a recent relapse.

When to consider switching treatments

You may need to switch DMTs if your current one is not controlling disease activity (you have a relapse or new lesions on MRI despite treatment), if you develop side effects you cannot tolerate, if you become pregnant or plan to become pregnant, or if you develop a condition that makes your current drug unsafe (such as a JC virus infection with natalizumab).

Switching is common and not a sign of failure. MS is variable, and what works for a time may stop working. Your neurologist will discuss the reasons for switching and what to expect from the new drug. Some switches happen quickly; others involve a washout period where you stop one drug before starting another.

The goal of modern MS treatment is to reach and maintain no evidence of disease activity (NEDA)—meaning no new relapses, no new or enlarging brain lesions on MRI, and no worsening disability. If your current treatment is not getting you to NEDA, a change may be warranted.

Frequently Asked Questions

Do I have to start a disease-modifying therapy right away after diagnosis?

Most neurologists recommend starting a DMT as soon as possible after diagnosis, ideally within weeks. Early treatment is associated with better long-term outcomes. However, the specific timing and choice of drug depend on your type of MS, disease activity, and other factors. Discuss the timing with your neurologist.

Can I stop taking my DMT once my MS is stable?

No. DMTs are meant to be taken long-term to prevent new relapses and new lesions. Stopping a DMT typically leads to increased disease activity within weeks or months. If you want to stop or are having side effects, talk to your neurologist about adjusting the dose or switching to a different drug rather than stopping altogether.

What is the difference between a relapse and disease progression?

A relapse is a sudden worsening of symptoms or new symptoms that last at least 24 hours and are separated from the previous relapse by at least 30 days. Progression is a gradual worsening of disability over time, independent of relapses. Relapsing-remitting MS has relapses; progressive MS has gradual worsening with few or no relapses.

Are there any MS treatments that reverse existing damage?

Current DMTs slow new damage but do not reverse damage that has already occurred. Research into remyelination therapies (drugs that repair damaged myelin) is ongoing, but none are yet available for routine use. The focus of current treatment is preventing new damage, not undoing old damage.

How often will I need MRI scans to monitor my treatment?

Most neurologists order an MRI 3 to 6 months after starting a new DMT to check for new lesions, then annually or every other year if you are stable. If you have a relapse or your neurologist suspects your treatment is not working, an MRI may be done sooner. The frequency depends on your disease activity and your neurologist's assessment.